MangoRx Introduces "MOJO" Pharmaceutical Compounded Formula Featuring Enclomiphene Citrate And Pregnenolone For Treatment Of Low Testosterone And Male Hormone Imbalances; Sold Exclusively On MangoRx's Website On A Subscription Basis At A Price Of $199 Per Month
MOJO to be offered as an Oral Dissolvable Tablet (ODT) marketed to younger male demographic as an alternative to PRIME Testosterone Replacement Therapy (TRT)
Dallas, Texas, June 04, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) ("MangoRx" or the "Company"), a company focused on developing, marketing, and selling a variety of men's health and wellness products in the area of erectile dysfunction (ED), hair growth, weight loss and hormone replacement therapies, is pleased to announce the development of proprietary formulations of Enclomiphene Citrate, Pregnenolone and Dehydroepiandrosterone (DHEA) in an Oral Dissolvable Tablet (ODT) aimed at restoring hormonal balance and naturally increasing testosterone levels in men. The new compounded product will be named "MOJO" and sold exclusively on MangoRx's website on a subscription basis at a price of $199 per month.